PCN238 COVID-19 Impact on Breast and Prostate Cancer Screening, Diagnosis, and Surgery: A Real-World Study from the Brazilian and Colombian Public Healthcare System Perspectives

Lima, Patrícia Verônica Pinheiro Sales; Werf, L. van der; Ferreira, R.; Kashiura, D.; Ono, Larissa Gabrielle Silva Ferreira; Julian, Guilherme Silva; Barbour, Julio; Hernández, F. J. Arribas

doi:10.1016/j.jval.2021.04.328

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In nine studies conducted in the USA, compared with the pre-pandemic period, a significant decrease in PSA tests was reported in the early months of the COVID-19 pandemic, ranging from 13.2% to 74% during the stay-at-home and reopening phases. [22][23][24][25][26][27][28][29] In the two Australian studies, the percentage rate of PCa testing using screening services dropped from 5% in 2019 to 2% in 2020 and 3% in 2020, respectively. 30 31 In Pakistan, the number of PSA tests performed decreased throughout the year 2020 compared with data for 2019, indicating the highest percentage (−51.8%) decline for PSA tests during the 2020 lockdown period.…”

Section: Prostate-specific Antibodymentioning

confidence: 99%

COVID-19 pandemic impact on screening and diagnosis of prostate cancer: a systematic review

Mostafavi Zadeh,

Tajik,

Gheytanchi

et al. 2023

BMJ Support Palliat Care

View full text Add to dashboard Cite

IntroductionThe healthcare level has been greatly affected by the COVID-19 pandemic compared with before the outbreak. This study aimed to review the impact of COVID-19 on the screening and diagnosis of prostate cancer (PCa).MethodThe current study was designed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020. The keywords used to perform the search strategy were COVID-19 and prostate neoplasms. The four primary electronic databases comprising PubMed/MEDLINE, Web of Science, Scopus and Embase were searched until 1 September 2022. After screening and selecting studies through the EndNote software, data were extracted from each included study by two independent authors. All studies were evaluated according to Newcastle–Ottawa Scale quality assessment tool.ResultsAs a result, 40 studies were included, categorised into two subjects. The majority of studies indicated a significant decrease in screening prostate-specific antibody tests during the COVID-19 pandemic compared with the pre-pandemic period, leading to delays in cancer diagnosis. The decrease in the number of diagnosed cases with low/intermediate stages to some extent was more than those with advanced stages. The PCa screening and diagnosis reduction ranged from nearly 0% to 78% and from 4.1% to 71.7%, respectively.ConclusionOur findings showed that during the COVID-19 lockdown, delays in PCa screening tests and diagnoses led to the negative health effects on patients with PCa. Thus, it is highly recommended performing regular cancer screening to reduce the impact of the COVID-19 lockdown.PROSPERO registration numberCRD42021291656.

show abstract